Evidence map›Paper›PMID 40748429›Full record

ArticleMolecular neurobiology2025

Dual Effect of Melatonin in Fetal Brain: Structural and Cellular Implications in a Rabbit Model of Intrauterine Growth Restriction.

Laia Guardia-Escote, Yvan Gómez, Mercè Fuentes-Amell, Carlota Rovira, Eduard Gratacós, Britta Anna Kühne, Marta Barenys, Miriam Illa

Abstract read
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laia Guardia-Escote *GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Yvan Gómez *BCNatal | Fetal Medicine Research Center, Hospital Clínic I Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Mercè Fuentes-AmellGRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Carlota RoviraDepartment of Anatomical Pathology, Hospital Sant Joan de Déu, Barcelona, Spain.
Eduard GratacósBCNatal | Fetal Medicine Research Center, Hospital Clínic I Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Britta Anna KühneGRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Marta BarenysGRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Miriam IllaBCNatal | Fetal Medicine Research Center, Hospital Clínic I Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain. miriam.illa@sjd.es.ORCID http://orcid.org/0000-0002-8366-830X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrauterine growth restriction (IUGR) is a condition in which the fetus fails to reach its genetic growth potential, often resulting in neurodevelopmental alterations. This study investigates the neuroprotective potential of gestational melatonin (MEL) treatment using an IUGR rabbit model. IUGR was induced by ligating the uteroplacental vessels of one uterine horn in pregnant rabbits, using the other horn as the control (CNT). Dams received either placebo (PLA) or MEL from gestational day 25 to 30, when pups were delivered by cesarean section. We performed a functional evaluation, followed by placental histopathology, oligodendrocyte quantification, neuronal arborization, and DAB (3, 3'-diaminobenzidine) staining of MEL receptors in the brain. IUGR groups exhibited significantly lower body weights and survival rates than CNTs, confirming successful model induction. Placental analysis indicated higher phase 2 ischemia in IUGR than CNTs, and reduced calcifications in MEL-treated groups. Brain analysis showed fewer oligodendrocytes and MEL receptors in PLA-treated IUGR groups compared to CNTs, partially reversed by MEL treatment. A dual response to MEL was observed in several endpoints, with beneficial effects on IUGR and detrimental effects on CNT groups. In conclusion, MEL demonstrates beneficial effects on the IUGR brain, particularly by increasing oligodendrocyte numbers, but its detrimental effects in CNT groups warrant caution in healthy pregnancies. These results indicate that substances can act as both therapeutic and toxic agents depending on physiological context, underscoring the need for further research to understand MEL's mechanisms and optimize treatment strategies.

Indexed as

BrainFetal Growth RetardationFetusMelatoninAnimalsDisease Models, AnimalFemaleOligodendrogliaPlacentaPregnancyRabbitsReceptors, MelatoninMelatoninReceptors, MelatoninIUGRMelatoninNeurodevelopmentPrenatal supplementsRabbit

Identifiers

PMID40748429
PMCPMC12559042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.